Overview

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-01-01

Target enrollment:

Participant gender:

Summary

This is a prospective, open-label, multicenter, single-arm clinical study designed to compare the efficacy and safety of neoadjuvant treatment with T-DXd in combination with an immune checkpoint inhibitor in patients with primary intermediate- to high-risk HR-positive, HER2-overexpressing early-stage breast cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Guangzhou Women and Children's Medical Center

Treatments:

Immune Checkpoint Inhibitors